Status:
COMPLETED
Rise Semi Compliant Balloon Study in Patient With CAD
Lead Sponsor:
Biosensors Europe SA
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Single arm, prospective, multi-center, trial designed to enrol approximately 66 patients. All patients will undergo PCI using at least one RISE SC balloon as per routine clinical practice and will be ...
Eligibility Criteria
Inclusion
- General Inclusion Criteria
- Subject must be at least 18 years of age.
- Subject or a legally authorised representative must provide written informed consent prior to any study related procedure.
- Subject must have stenotic lesion(s) in native coronary arteries or bypass grafts that are suitable for percutaneous coronary intervention.
- Subject must agree to undergo all protocol-required follow-up procedures.
- Subject must agree not to participate in any other clinical study during hospitalisation for the index procedure.
- Angiographic Inclusion Criteria All angiographic inclusion criteria are based on visual estimation.
- De novo or restenotic lesions in native coronary arteries or bypass grafts.
- A maximum of two lesions, with either both in one vessel or one lesion in each of two vessels.
- The target lesion(s) must have a diameter stenosis of ≥ 50% by visual estimation or online quantitative coronary angiography (QCA) and may include chronic total occlusions (CTO).
Exclusion
- General Exclusion Criteria
- Planned use of a non-study angioplasty balloon during the procedure for pre-dilatation or dilatation of the lesion.
- Subject has a known hypersensitivity or contraindication to aspirin, heparin/bivalirudin, other anti-platelet medications, or sensitivity to contrast media, which cannot be adequately pre-treated.
- Subject has a platelet count \< 100,000 cells/mm3 or \> 700,000 cells/mm3.
- Subject is currently participating in an investigational study that may confound the treatment or outcomes of this study.
- Subject is pregnant or nursing. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to the index procedure per site standard test.
- Angiographic Exclusion Criteria All angiographic exclusion criteria are based on visual estimation.
- Unprotected left main coronary artery disease
- More than two lesions requiring treatment. Tandem lesions, defined as multiple, focal lesions that can be covered by one balloon, will be considered as a single lesion.
- Coronary artery spasm in the absence of significant stenosis.
- Anticipated need for plaque modification using rotational/orbital atherectomy or intravascular lithotripsy. Note: The use of scoring or cutting balloons after (pre)-dilatation with the study device is allowed.
- Additional clinically significant lesion(s) in any coronary arteries or bypass grafts for which PCI may be required during hospitalization for the index procedure (in-hospital staged PCI).
Key Trial Info
Start Date :
January 31 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 9 2022
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT04796038
Start Date
January 31 2022
End Date
November 9 2022
Last Update
January 25 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
CHUV
Lausanne, Canton of Vaud, Switzerland, 1011
2
HVS
Sion, Valis, Switzerland, 1950
3
HUG
Geneva, Switzerland, 1205